What Happened?
New York, NY-based Bridge-Medicines Appointed William Polvino as Chief Executive Officer And Director
About the Company
Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine.
About the Person
William Polvino is Chief Executive Officer And Director at Bridge Medicines. Previously, William held various senior HR leadership roles in the industry.
Info Source
News
Short Profile